Literature DB >> 143966

The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor, with plasmin, thrombin, trypsin and chymotrypsin.

J Edy, D Collen.   

Abstract

The inhibition of plasmin, (EC 3.4.21.7), thrombin (EC 3.4.21.5), trypsin (EC 3.4.21.4) and chymotrypsin (EC 3.4.21.1) by antiplasmin, the recently described fast-reacting plasmin inhibitor of human plasma, was studied. To determine the quantitative importance of antiplasmin relative to the other plasma protease inhibitors, enzyme inhibition assays were performed on whole plasma and on plasma specifically depleted in antiplasmin, after addition of excess enzyme. Plasmin was the only enzyme for which the inhibitory capacity of antiplasmin-depleted plasma was lower than that of normal plasma. To determine the affinity of the enzymes for antiplasmin, as compared to the other inhibitors, various amounts of enzymes were added to normal plasma and the formation of enzyme-antiplasmin complexes studied by crossed immunoelectrophoresis using specific antisera against antiplasmin. Plasmin and trypsin, but not thrombin or chymotrypsin formed complexes with antiplasmin. It is concluded that antiplasmin is the only fast-reacting plasmin inhibitor of human plasma. It is also a fast-reacting inhibitor of trypsin but only accounts for a very small part of the fast-reacting trypsin-inhibitory activity of plasma. This can be explained by the low concentration of antiplasmin (1 muM) in normal plasma, compared to the other inhibitors (e.g. alpha1-antitrypsin: 40-80 muM).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 143966     DOI: 10.1016/0005-2744(77)90098-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Inactivation of various proteinase inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens.

Authors:  A Molla; T Akaike; H Maeda
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

2.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 3.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

Review 4.  Natural inhibitors of fibrinolysis.

Authors:  D Collen
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

5.  Potential Anticoagulant Activity of Trypsin Inhibitor Purified from an Isolated Marine Bacterium Oceanimonas Sp. BPMS22 and its Kinetics.

Authors:  B S Harish; Kiran Babu Uppuluri
Journal:  Mar Biotechnol (NY)       Date:  2018-08-18       Impact factor: 3.619

6.  Molecular mechanism of complex infection by bacteria and virus analyzed by a model using serratial protease and influenza virus in mice.

Authors:  T Akaike; A Molla; M Ando; S Araki; H Maeda
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Effect of cell density on thrombin binding to a specific site on bovine vascular endothelial cells.

Authors:  J Isaacs; N Savion; D Gospodarowicz; M A Shuman
Journal:  J Cell Biol       Date:  1981-09       Impact factor: 10.539

8.  New Insights on Plasmin Long Term Stability and the Mechanism of Its Activity Inhibition Analyzed by Quartz Crystal Microbalance.

Authors:  Marek Tatarko; Ilia N Ivanov; Tibor Hianik
Journal:  Micromachines (Basel)       Date:  2021-12-29       Impact factor: 2.891

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.